On the stock market since 2021, it operates in the world of health and science. It has 682 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 83% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $201.5M a year. A small number, but proof the product has real buyers.
There is $261.5M in the vault; even if every debt were paid off, $237.8M would remain.
A loss of $66.5M against $201.5M in annual sales.
The growth engine is running at low revs right now. Report-card grade: 13/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 38/100.
On our five-subject report card, CTKB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CTKB is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.